Looking for kids, teens, and young adults with With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)for a study of an investigational drug combination help people feel better, have fewer side effects, and prevent cancer from returning.
Seeking children and young adults 31 years old or younger who have been newly diagnosed with standard risk B-cell Acute Lymphoblastic Leukemia (B-ALL), Down syndrome B ALL or localized B-cell Lymphoblastic Lymphoma (B-LLy) for a study of chemotherapy.
Children and young adults up to age 25 with High-Risk B-cell acute lymphoblastic leukemia (B-ALL) sought for a study of an investigational drug in combination of chemotherapy based on individual disease characteristics to improve 5-year disease-free survival (DFS).
Seeking children and young adults whose CD22+ B-Acute Lymphoblastic Leukemia (B ALL) has come back (relapsed) after treatment or has not responded (refractory) for a study of an investigational drug. While the investigational drug has been approved for use adults with leukemia, it has not yet been approved for use in children.
Seeking infants aged up to 1 year with newly diagnosed B-acute lymphoblastic leukemia (B-ALL) or acute leukemia of ambiguous lineage (ALAL) that has not yet been treated for a study of adding an investigational drug to the usual chemotherapy.